SELEGILINE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Selegiline, and what generic alternatives are available?
Selegiline is a drug marketed by Apotex, Lannett Co Inc, Novitium Pharma, Rising, Apotex Inc, Bayshore Pharms Llc, Chartwell Molecules, Cosette, Dash Pharms Natco, G And W Labs Inc, I3 Pharms, and Somerset. and is included in fourteen NDAs.
The generic ingredient in SELEGILINE is selegiline hydrochloride. There are seventeen drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the selegiline hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Selegiline
A generic version of SELEGILINE was approved as selegiline hydrochloride by I3 PHARMS on April 1st, 1997.
Summary for SELEGILINE
US Patents: | 0 |
Applicants: | 12 |
NDAs: | 14 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for SELEGILINE |
DailyMed Link: | SELEGILINE at DailyMed |
Recent Clinical Trials for SELEGILINE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
University of Ibadan | Phase 1/Phase 2 |
László Mangel | Phase 2 |
E-Group ICT Software Informatikai Zrt. | Phase 2 |
Medical Subject Heading (MeSH) Categories for SELEGILINE
US Patents and Regulatory Information for SELEGILINE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Apotex | SELEGILINE HYDROCHLORIDE | selegiline hydrochloride | CAPSULE;ORAL | 075321-001 | Dec 4, 1998 | AB | RX | No | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
Chartwell Molecules | SELEGILINE HYDROCHLORIDE | selegiline hydrochloride | TABLET;ORAL | 074565-001 | Aug 2, 1996 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Rising | SELEGILINE HYDROCHLORIDE | selegiline hydrochloride | CAPSULE;ORAL | 206803-001 | Apr 2, 2019 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |